There are 3161 resources available
Conclusions and perspectives
Presenter: Samra Turajlic
Session: Are we targeting the right antigens?
Resources:
Webcast
238MO - PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
Presenter: Francois Cherifi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Q&A
Session: Dissecting Cancer of Unknown Primary: Case presentation and expert insights
Resources:
Webcast
Q&A
Session: Proffered paper session: Melanoma and other skin tumours
Resources:
Webcast
LBA14 - Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
Presenter: Sabine Linn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA56 - Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Presenter: Gregory Riely
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 236MO, 237MO, 238MO and LBA14
Presenter: Lisa Carey
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
LBA57 - Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12
Presenter: Fabrice Barlesi
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
LBA15 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Meghna Trivedi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)
Presenter: David Planchard
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast